Form 4: Myriad Genetics Chief Accounting Officer, Natalie Munk, Reports Acquisition of 7,500 Shares

Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports acquiring 7,500 shares of common stock as part of a restricted stock unit grant.

Summary

• Natalie Munk, the Chief Accounting Officer of Myriad Genetics, filed a Form 4 on March 18, 2024, reporting a transaction that occurred on March 14, 2024.
• The transaction involved the acquisition of 7,500 shares of Myriad Genetics common stock.
• These shares were acquired through a grant of time-based restricted stock units under the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• Each restricted stock unit represents the right to receive one share of common stock, vesting in three equal annual installments starting one year from the grant date.
• Following the reported transaction, Munk beneficially owns 46,728 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The acquisition of shares by an officer is generally viewed neutrally to slightly positive, suggesting confidence in the company.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date, suggesting a multi-year alignment of the officer's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices using restricted stock units.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns management's interests with the company's performance.

Key Dates